ACIP
Digital and print versions of schedules for healthcare professionals.
Recent updates to guidance for immunocompromised persons can be found in the:
August 30, 2021, 10:00 a.m. – 4:30 p.m. is a virtual COVID-19 meeting.
No registration is required.
Agenda – August 30, 2021 pdf icon[1 page]
1600 Clifton Road, N.E., Mailstop H24-8
Atlanta, GA 30329-4027
acip@cdc.gov
To receive email updates about this page, enter your email address:
June 2021
ACIP approved the following recommendations by majority vote at its June 24-25, 2021 meeting.
- ACIP recommends 3-doses of Dengvaxia administered 6 months apart at month 0, 6, and 12, in persons 9-16 years of age with a laboratory confirmation of previous dengue infection and living in endemic areas.
- ACIP affirms the updated MMWR Recommendations and Reports, “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2021-22 Influenza Season.”
- ACIP recommends a 2-dose [0, 7 days] intramuscular rabies vaccine series in immunocompetent persons <18 years of age for whom rabies vaccine pre-exposure prophylaxis (PrEP) is indicated.
- ACIP recommends an intramuscular booster dose of rabies vaccine, as an alternative to a titer check, for immunocompetent persons <18 years of age who have sustained and elevated risk for only recognized rabies exposures (i.e., those in risk category #3 of rabies PrEP recommendations table). The booster dose should be administered no sooner than day 21 but no later than 3 years after the 2-dose PrEP series.
These recommendations have been adopted by the CDC Director and will become official once published in MMWR.
February 2021
ACIP approved the following recommendations by majority vote at its February 24-25, 2021 meeting.
- ACIP recommends a 2-dose [0, 7 days] intramuscular rabies vaccine series in immunocompetent persons ≥18 years of age for whom rabies vaccine pre-exposure prophylaxis (PrEP) is indicated.
- ACIP recommends an intramuscular booster dose of rabies vaccine, as an alternative to a titer check, for immunocompetent persons ≥18 years of age who have sustained and elevated risk for only recognized rabies exposures (i.e., those in risk category #3 of rabies PrEP recommendations table). The booster dose should be administered no sooner than day 21 but no later than 3 years after the 2-dose PrEP series.
These recommendations have been adopted by the CDC Director and will become official once published in MMWR.